The 2G UNic technology increases transcription and translation rates by combining novel genetic elements and can be easily combined with other protein expression-enhancing technologies to improve performance.

Under the agreement, Gilead will gain nonexclusive commercial rights for application of ProteoNic's technology platform for the development of its proprietary products from mammalian cells.

Financial details of the agreement were not disclosed.If you like this content, please share it with a colleague!